Price
$6.65
Decreased by -6.47%
Dollar volume (20D)
8.96 M
ADR%
3.83
Earnings report date
May 12, 2025
Shares float
547.94 M
Shares short
2.71 M [0.49%]
Shares outstanding
257.44 M
Market cap
7.13 B
Beta
0.69
Price/earnings
35.00
20D range
6.57 8.27
50D range
6.57 8.81
200D range
5.79 9.96

Grifols,S. A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally.

The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma, and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factor VIII/von Willebrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.

It also markets diagnostic testing equipment, reagents, and other equipment; offers biological products and manufacturing services; and manufactures and sells plasma to third parties.

In addition, the company offers Yimmugo IDP, an immunology drug; Yimmugo PTI, a hematology drug; and Prolastin vials, a pulmonology drug.

Further, it develops Xembify Pre-filled syringes, Gamunex Bags, and FlexBag; Xembify Biweekly dosing, Fibrinogen, and VISTASEAL; Prolastin-C AADT and Fostamatinib; Xembify " CLL, Albumina 20% and 5%, and Trimodulin; Alfa-1 AT 15%, GRF6019, GRF6021, Aßvac402, AKST4290, and AKST4290; GIGA 2339 and GIGA564; and recIG, Alfa-1 AT - in non-cystic fibrosis bronchiectasis, and OSIG that are in pre-clinical stage.

It has collaboration agreements with Canadian Blood Services to supply grains of Immunoglobulin.

The company was founded in 1909 and is headquartered in Barcelona, Spain.

  • Quarterly earnings
  • Annual earnings
Reported date EPSChange YoY EstimateSurprise
Feb 26, 25 0.11
Decreased by -22.79%
-
Nov 7, 24 0.17
Increased by +54.55%
0.24
Decreased by -29.17%
Jul 30, 24 0.15
Decreased by -9.04%
0.21
Decreased by -28.57%
May 16, 24 0.07
Increased by +59.82%
0.15
Decreased by -53.33%
Feb 29, 24 0.14
Increased by +118.41%
0.22
Decreased by -36.36%
Nov 2, 23 0.11
Increased by +N/A%
0.22
Decreased by -50.00%
Jul 27, 23 0.16
Increased by +24.92%
0.20
Decreased by -17.18%
May 15, 23 0.04
Increased by +N/A%
0.16
Decreased by -72.47%
  • Quarterly financials
  • Annual financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 24 1.79 B
Increased by +12.24%
51.69 M
Decreased by -13.19%
Increased by +2.88%
Decreased by -22.65%
Jun 30, 24 1.82 B
Increased by +9.28%
14.84 M
Decreased by -75.28%
Increased by +0.82%
Decreased by -77.38%
Mar 31, 24 1.63 B
Decreased by -5.08%
21.42 M
Increased by +6.72%
Increased by +1.32%
Increased by +12.44%
Dec 31, 23 1.77 B
Increased by +3.32%
55.99 M
Increased by +178.99%
Increased by +3.16%
Increased by +170.03%
Sep 30, 23 1.60 B
Increased by +3.66%
59.54 M
Increased by +33.63%
Increased by +3.73%
Increased by +28.91%
Jun 30, 23 1.66 B
Increased by +7.81%
60.03 M
Decreased by -33.54%
Increased by +3.61%
Decreased by -38.36%
Mar 31, 23 1.71 B
Increased by +42.94%
20.07 M
Increased by +151.40%
Increased by +1.17%
Increased by +135.96%
Dec 31, 22 1.71 B
Increased by +N/A%
20.07 M
Increased by +N/A%
Increased by +1.17%
-
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY